{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-026781","form_type":"8-K","ticker":"PVCT","cik":"0000315545","company_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","filed_at":"2022-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.759092+00:00","generated_at":"2026-06-23T07:33:50.538530+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Provectus Biopharmaceuticals approves up to $5M convertible note financing","bullets":["Board approved term sheet for up to $5M in convertible notes; proceeds fund drug discovery and G&A.","Notes bear 8% interest, mature in 12 months, convertible into Series D-1 Preferred at $2.8620/share.","Series D-1 Preferred shares convert into 10 common shares each.","Company also closed $2.335M from previously disclosed 2021 convertible note financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-026781","json":"https://secwatch.observer/filing/0001493152-22-026781.json","markdown":"https://secwatch.observer/filing/0001493152-22-026781.md","text":"https://secwatch.observer/filing/0001493152-22-026781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/315545/000149315222026781/0001493152-22-026781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/315545/000149315222026781/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:33:50.538530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}